Rosetta Genomics To Host Business Update Conference Call on April 10, 2013

PHILADELPHIA, and REHOVOT, Israel, March 25, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that following the close of the U.S. stock market on Friday, March 22, 2013, the Company filed its Annual Report on Form 20-F for the year ended December 31, 2012 with the U.S. Securities and Exchange Commission ("SEC"). The Form 20-F includes audited annual consolidated financial statements, as well as additional information regarding the Company. The Form 20-F is available at www.sec.gov and at www.rosettagenomics.com.  

Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, and Ron Kalfus, Chief Financial Officer of Rosetta Genomics, will host a conference call on Wednesday, April 10, 2013 at 10:00 a.m. Eastern (7:00 a.m. Pacific) to provide an update on the Company's business and respond to questions.

Individuals interested in listening to the conference call may do so by dialing (866) 239-5859, or for international callers (702) 495-1913.  The conference ID number is 27774171.  The call is also being webcast, and can be accessed on the investor relations section of the Company's Web site at www.rosettagenomics.com and also at www.streetevents.com.

A telephone replay will be available through April 16, 2013 by dialing (855) 859-2056 or for international callers (404) 537-3406, and entering the Conference ID number 27774171.  The webcast will be available for 30 days following the completion of the call.

About miRview^® Products
miRview^® are a series of microRNA-based diagnostic products offered by Rosetta Genomics. miRview^® mets² accurately identifies the primary tumor type in primary and metastatic cancer including CUP. miRview^® meso diagnoses mesothelioma, a cancer connected to asbestos exposure.  miRview^® lung accurately identifies the four main subtypes of lung cancer using small amounts of tumor cells. miRview^® kidney accurately classifies the four most common kidney tumors: clear cell renal cell carcinoma (RCC), papillary RCC, chromophobe RCC and oncocytoma.  miRview^® tests are designed to provide objective diagnostic data; it is the treating physician's responsibility to diagnose and administer the appropriate treatment.  In the U.S. alone, Rosetta Genomics estimates that 200,000 patients a year may benefit from the miRview^® mets² test, 60,000 from miRview^® meso, 54,000 from miRview^® kidney and 226,000 patients from miRview^® lung. The Company's assays are offered directly by Rosetta Genomics in the U.S., and through distributors around the world. For more information, please visit www.mirviewdx.com. Parties interested in ordering the test can contact Rosetta Genomics at (215) 382-9000 ext. 309.

About Rosetta Genomics
Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics.  Founded in 2000 Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong patent position and proprietary platform technologies, Rosetta is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools. Rosetta's miRview® product line is commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.  Frost & Sullivan recognized Rosetta Genomics with the 2012 North American Next Generation Diagnostics Entrepreneurial Company of the Year Award.

Forward-Looking Statement Disclaimer
Various statements in this release concerning Rosetta's future expectations, plans and prospects, including without limitation, statements relating to Rosetta's strategic plan, Rosetta's development or commercialization of molecular diagnostics or therapeutics, the market acceptance of Rosetta's miRview^® assays, particularly miRview^® mets², Rosetta's capitalization of its microRNA platform, Rosetta's patent position and Rosetta's development of personalized medicine products constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed in the "Risk Factors" section of Rosetta's Annual Report on Form 20-F for the year ended December 31, 2012 as filed with the SEC. In addition, any forward-looking statements represent Rosetta's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact: 
Rosetta Genomics          
Ken Berlin, President & CEO                                        
(215) 382-9000, ext. 326                                                                  
[email protected]

Investor Contacts:    
LHA                                                     
Anne Marie Fields
(212) 838-3777
[email protected]
or
Bruce Voss
310-691-7100
[email protected]

SOURCE Rosetta Genomics Ltd.